{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:39:34Z","timestamp":1778773174484,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bcp.2020.114133","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T11:16:40Z","timestamp":1593775000000},"page":"114133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR"],"prefix":"10.1016","volume":"180","author":[{"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris A.L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme W.","family":"Carlile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114133_b0005","unstructured":"ECFS Patient Registry \u2013 Annual Data Report 2017. Available at: https:\/\/www.ecfs.eu\/sites\/default\/files\/general-content-images\/working-groups\/ecfs-patient-registry\/ECFSPR_Report2017_v1.3.pdf."},{"key":"10.1016\/j.bcp.2020.114133_b0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancer Respir. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114133_b0020","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2020.114133_b0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.114133_b0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114133_b0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0040","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0045","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.114133_b0050","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/13993003.01192-2015","article-title":"Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids","volume":"48","author":"Dekkers","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2020.114133_b0060","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of corectors rescues CFTR transmembrane-domain mutants by mitigating their interactions with proteostasis","volume":"41","author":"Lopes-Pacheco","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2020.114133_b0065","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/cbic.200700027","article-title":"Correctors of protein trafficking defects identified by a novel high-throughput screening assay","volume":"8","author":"Carlile","year":"2007","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bcp.2020.114133_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.chembiol.2010.11.016","article-title":"Identification of a NBD1-binding pharmacological chaperon that corrects the trafficking defect of F508del-CFTR","volume":"18","author":"Sampson","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2020.114133_b0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1097-2765(00)80196-3","article-title":"Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis","volume":"4","author":"Chang","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2020.114133_b0080","doi-asserted-by":"crossref","first-page":"17891","DOI":"10.1073\/pnas.0608312103","article-title":"Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms","volume":"103","author":"Roxo-Rosa","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2020.114133_b0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2020.114133_b0090","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1073\/pnas.0800254105","article-title":"Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function","volume":"105","author":"Serohijos","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2020.114133_b0095","doi-asserted-by":"crossref","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","article-title":"The cystic fibrosis-causing mutation delF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis","volume":"285","author":"Thibodeau","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114133_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.200401035","article-title":"COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code","volume":"167","author":"Wang","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2020.114133_b0105","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00018-018-2896-7","article-title":"Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation","volume":"75","author":"Canato","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2020.114133_b0110","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1038\/srep09038","article-title":"Protein traffic disorders: an effective high-throughput fluorescence microscopy pipeline for drug discovery","volume":"5","author":"Botelho","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114133_b0115","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00285.2019","article-title":"The dual phosphodiesterase 3\/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants","author":"Turner","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bcp.2020.114133_b0120","doi-asserted-by":"crossref","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2020.114133_b0125","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1038\/s41598-018-29276-y","article-title":"A novel triple combination of pharmacological chaperones improves F508del-CFTR correction","volume":"8","author":"Carlile","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114133_b0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis","volume":"2","author":"Awatade","year":"2014","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2020.114133_b0135","doi-asserted-by":"crossref","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator of ivacaftor abrogates pharmacologial correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0140","doi-asserted-by":"crossref","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2020.114133_b0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2019.06.010","article-title":"Theranostics by Testing CFTR modulators in patient-derived materials: the current status and a proposal for subjects with rare CFTR mutations","volume":"18","author":"Amaral","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.bcp.2020.114133_b0150","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114133_b0155","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of Cell Background on Pharmacological Rescue of Mutant CFTR","volume":"294","author":"Pedemonte","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2020.114133_b0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","article-title":"DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers","volume":"23","author":"Rowe","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.114133_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.152","article-title":"Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR","volume":"3","author":"Farinha","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bcp.2020.114133_b0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1096\/fj.12-216119","article-title":"Correctors of \u0394F508 CFTR Restore global conformation maturation without thermally stabilizing the mutant protein","volume":"27","author":"He","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2020.114133_b0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bph.13365","article-title":"Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor)","volume":"173","author":"Matthes","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114133_b0180","first-page":"666","article-title":"VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface","volume":"21","author":"Eckford","year":"2014","journal-title":"Cell Biol"},{"key":"10.1016\/j.bcp.2020.114133_b0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cbic.201500620","article-title":"Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis","volume":"17","author":"Lopes-Pacheco","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bcp.2020.114133_b0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1091\/mbc.e10-09-0760","article-title":"The endoplasmic reticulum-associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate RMA1 E3-dependent degradation of nascent CFTRDeltaF508","volume":"33","author":"Grove","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2020.114133_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119796","article-title":"Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation","volume":"10","author":"Rapino","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114133_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:14:32Z","timestamp":1757769272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"alternative-id":["S0006295220303695"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114133","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114133"}}